New RSV vaccine for older adults can result in individual and societal cost savings, benefits

Vaccination against respiratory syncytial virus for adults over 60 is likely to be cost-effective by preventing illness, hospitalizations, lost quality of life and deaths, according to new research.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup